A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Metformin, an OCT2 Substrate, in Healthy Subjects When Administered Alone and in Combination With a Single Oral Dose of Vandetanib (CAPRELSA) 800 mg.
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2016
At a glance
- Drugs Metformin; Vandetanib
- Indications Cancer; Diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Sanofi
- 22 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 22 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.